#OMMERCIALûREALûESTATEûBROKERAGEûlRMû
CUSHMAN & WAKEFIELD, which could raise
53BN ûISûALSOûLOOKINGûFORûAûPRE
,ABORû$AYû
DEBUTûANDûCOULDûOPTûTOûLAUNCH
With second quarter earnings now front
ANDûCENTRE ûSECONDARYûACTIVITYûDURINGûTHEû
PASTûWEEKûWASûLIMITEDûANDûCONlNEDûTOû
smaller deals, though there are some large
PENDINGû-!ûlNANCINGSûTHATûMAYûSEEKûTOû
PRICEûSOON
ART OF THE BIOTECH DEALRUBIUS THERAPEUTICS ûAûREDûBLOODûCELLûSPECIALIST û
DELIVEREDûAûRATHERûSTAIDûûDAY
ONEûGAINûONû
7EDNESDAYûINûCLOSINGûATû53
-UCHûOFûTHEûACTIONûWASûEARLYûINûITSûDEBUTû
SESSIONûANDûATûMUCHûHIGHERûLEVELS ûWITHûAû
53û67!0
v7EûHAVEûSEENûAûLOTûOFûTHEûBIOTECHSûOPENû
HUGEûONûHIGHûVOLUMEûANDûTHENûCOMEûDOWNû
TOûEARTH vûSAIDûONEûCAPITALûMARKETSûBANKERû
v)NSTITUTIONSûlLLûOUTûTHEIRûPOSITIONSûANDûTHENû
THEREûISûNOûONEûLEFTûTOûBUYv
In the largest biotech IPO of the year so
FAR û2UBIUSûSECUREDû53MûONû4UESDAYû
NIGHTûAFTERûSELLINGûANûUPSIZEDûMûSHARESû
ATû53 ûABOVEûTHEû53
ûMARKETINGû
RANGEûANDûACCELERATEDûBYûONEûDAY
2UBIUSûISûNOTûEXPECTEDûTOûDELIVERû
MEANINGFULûNEWSmOWûUNTILûITûlLESûAûNEWû
DRUGûAPPLICATIONûWITHûTHEû&$!ûINûTHEûlRSTû
QUARTERûOFûû5NTILûTHEN ûTRADINGûVOLUMEû
SHOULDûREMAINûTHIN
3HARESûOFûALLAKOS ûTHEûINmAMMATORYû
DISEASEûSPECIALIST ûPROVEDûTOûBEûINûSHORTû
SUPPLYûASûITûCLOSEDûITSûDEBUTûSESSIONûATû
53ûONû4HURSDAY ûANûIMPRESSIVEûû
ABOVEûITSû53Mû)0/ûPRICE
!LLAKOSûPRICEDûMûSHARESûATû53ûONû
7EDNESDAYûNIGHT ûVERSUSûTHEûMARKETEDû
OFFERINGûOFûMûSHARESûATû53
4HEûDEALûWASûHEAVILYûOVERSUBSCRIBEDû
and Goldman Sachs and Jefferies were able to
SCALEûBACKûINSIDERûREQUESTSûINûORDERûTOû
MAKEûWAYûFORûNEWûINVESTORSû
ûTHEû
AFTERMARKETûBUYERS
)NSIDERSûENDEDûUPûTAKINGû53MûAFTERû
PUTTINGûINûFORûUPûTOû53Mû!ûCONCURRENTû
PRIVATEûPLACEMENTûWITHû.EWû%NTERPRISEû
!SSOCIATESûWASûSLASHEDûTOû53MûFROMû
53MûORIGINALLY
!ûDELAYEDûOPENINGûSAWûAûlRSTûPRINTûATû
AMûATû53ûONûVOLUMEûOFû û
AûSIZABLEûPORTIONûOFûTHEûMûSHARESûSOLDûONû
THEûOFFERINGû4HEûSTOCKûRANûTHROUGHOUTûTHEû
AFTERNOONûANDûTRADEDûWITHûAû53û
67!0
0ROCEEDSûBOOSTû!LLAKOSûCASHûTOû
53MûONûAûPROûFORMAûBASIS
!LLAKOSûDRUGûHASûPOTENTIALûTOûTREATûAû
BROADûRANGEûOFûINmAMMATORYûDISORDERSûTHATû
AREûASSOCIATEDûWITHûCERTAINûWHITEûBLOODûCELLSû
4HEûCOMPANYûISûCURRENTLYûRUNNINGû0HASEû))û
TRIALSûINûTWOûINDICATIONSûANDûHASûPLANSûTOû
INITIATEû0HASEû)ûTRIALSûINûTWOûOTHERûDISEASESû
0ROCEEDSûAREûENOUGHûTOûFUNDûALLûFOURûTRIALSCRINETICS HIGHLIGHTS BIOTECH’S
BUSY WEEKCRINETICS PHARMACEUTICALSûRANûTOûAûûlRSTû
DAYûGAINûONû7EDNESDAYûAFTERûPRICINGûAû
53Mû)0/ûTHATûWASûUPSIZEDûANDûPRICEDûATû
THEûHIGHûENDûOFûTHEûRANGE
JP Morgan, Leerink Partners and Piper Jaffray
SAWûNOûPUSHBACKûASûTHEYûPRICEDûMûSHARESû
ATû53ûAFTERûMARKETINGûMûSHARESûATû
53
0RICINGûONûTHEûSAMEûNIGHTûASû2UBIUSû
4HERAPEUTICS û#RINETICSûWASûSOMETHINGûOFûAû
DARKûHORSEû#RINETICSûRANûUPûûTOû53û
BEFOREûCLOSINGûTHEûlRSTûDAYûOFûTRADINGûATû
53Crinetics, which is focused on endocrine
DISEASESûNOWûHASû53MûOFûCASH û
ENOUGHûTOûFUNDûOPERATIONSûTHROUGHûTHEû
NEXTûûMONTHSûACCORDINGûTOûTHEû
PROSPECTUS
Its lead drug is a treatment for
acromegaly, a growth disorder that can lead
TOûGIGANTISMûINûPATIENTS ûSUCHûASûTHEûLATEû
PROFESSIONALûWRESTLERû!NDREûTHEû'IANT
)NûSTARKûCONTRAST ûCONSTELLATION
PHARMACEUTICALS turned in the worst debut
OFûTHEûYEAR ûTUMBLINGûûONû
7EDNESDAYûFROMûITSû53û)0/ûPRICEûINû
CLOSINGûATû53 ûWITHûAû53û
67!0
$ESPITEûMID
POINTûPRICING ûJP Morgan,
Jefferies and BMO Capital Markets cut the
PUBLICûOFFERINGûFROMûMûTOûMûSHARESûANDû
UPPEDûINSIDERûPARTICIPATIONûFROMû53MûTOû
53M
0UTûANOTHERûWAY ûTHEûPUBLICûCOMPONENTûOFû
THEû53Mû)0/ûWASûAûMEREû53Mû
#ONSTELLATIONûRAISEDû53MûINûAû&EBRUARYû
SERIESû&ûROUNDûATûANûEQUIVALENTûPRICEûOFû
53
)TûNOWûHASû53MûOFûFUNDINGûFORûAûNEWû
CLASSûOFûEPIGENETICûCANCERûDRUGSû4HEûDRUGSû
are small molecules that inhibit abnormal
GENEûEXPRESSIONûINûTUMOURSûANDûTRIGGERûANû
IMMUNEûRESPONSEûAGAINSTûCANCER
4HEûCOMPANYûEXPECTSûTOûBEûSUFlCIENTLYû
FUNDEDûTHROUGHûTHEûlRSTûQUARTERûOFû
REPLIMUNEûCULMINATEDûTHEûWEEKSûBIOTECHû
)0/ûACTIVITYûWITHûAûMIDPOINTûOUTCOMEûONûITSû
53Mû)0/
4HEûSTOCKûDEBUTEDûONû&RIDAYûMORNINGûATû
53 ûUPûûFROMûTHEû53ûOFFERûSETûONû
MûSHARESûSOLDûONûTHEû)0/
JP Morgan, Leerink Partners and BMO Capital
Markets WEREûTHEûJOINTûBOOKRUNNERSû4HEû
DEALûWASûBACKEDûWITHûUPûTOû53MûOFû
INSIDERûSUPPORTECM DEALS: WEEK ENDING 20/7/2018
Stock Country Date Amount Price Deal type Bookrunner(s)
Establishment Labs Costa Rica 18/07/2018 US$66.9m US$18.00 IPO (primary) Jefferies, Cowen
Qilu Expressway China 16/07/2018 HK$1.25bn HK$2.50 IPO (primary) China Securities Intl, Zhongtai Intl, CCB Intl,
GF Securities, Guotai Junan Intl
E-House (China) Enterprise China 16/07/2018 HK$4.64bn HK$14.38 IPO (primary) CICC, Credit Suisse, HSBC
Prysmian Italy 19/07/2018 €500m €15.31 Rights issue Banca IMI, Goldman Sachs, Mediobanca
AC Immune Switzerland 18/07/2018 US$86.8m US$11.75 Rights issue/Accelerated bookbuild (Primary) Jefferies, Leerink Partners, UBS
Hays UK 19/07/2018 £77.6m 194p Accelerated bookbuild (Secondary) Barclays
AC Immune US 18/07/2018 US$91.2m US$11.75 Follow-on (primaray Jefferies, Leerink Partners, UBS
Allakos US 18/07/2018 US$129.6m US$18.00 IPO (primary) Goldman Sachs, Jefferies
Cara Therapeutics US 18/07/2018 US$85.5m US$19.00 Follow-on (primaray Jefferies, BAML, Piper Jaffray, Stifel
Carbonite US 18/07/2018 US$204.9m US$37.50 Follow-on (primary, secondary) Barclays, Jefferies, RBC Capital Markets
Constellation Pharmaceuticals US 18/07/2018 US$60.0m US$15.00 IPO (primary) JP Morgan, Jefferies, BMO Capital Markets
Crinetics Pharmaceuticals US 17/07/2018 US$102.0m US$17.00 IPO (primary) JP Morgan, Leerink Partners, Piper Jaffray
Evolus US 18/07/2018 US$80.0m US$20.00 Follow-on (primary, secondary) Cantor, Mizuho
NanoString Technologies US 17/07/2018 US$50.0m US$12.50 Follow-on (primary) JP Morgan, UBS
Redfin US 18/07/2018 US$75.6m US$18.00 Follow-on (primary) Goldman Sachs, BAML, RBC, ALLN
Replimune US 18/07/2018 US$100.5m US$15.00 IPO (primary) JP Morgan, Leerink Partners, BMO Capital Markets
Rubius Threrapeutics US 17/07/2018 US$241.1m US$23.00 IPO (primary) JP Morgan, MS, Jefferies, Leerink Partners
Tilray US 18/07/2018 US$153.0m US$17.00 IPO (primary) Cowen, Roth, Northland Capital